Apcin

Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C (Cdc20) ) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis[1][2][3].

Product Specifications

CAS Number

[300815-04-7]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

APC; Mitosis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/apcin.html

Purity

99.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCCN1C([N+]([O-])=O)=CN=C1C)NC(NC2=NC=CC=N2)C(Cl)(Cl)Cl

Molecular Formula

C13H14Cl3N7O4

Molecular Weight

438.65

Precautions

H315, H319, H335

References & Citations

[1]Katharine L Sackton, et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature. 2014 Oct 30;514 (7524) :646-9.|[2]Katherine V Richeson, et al. Paradoxical mitotic exit induced by a small molecule inhibitor of APC/C Cdc20. Nat Chem Biol. 2020 May;16 (5) :546-555.|[3]Susanne Lub, et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016 Jan 26;7 (4) :4062-76.